<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01297634</url>
  </required_header>
  <id_info>
    <org_study_id>191622</org_study_id>
    <secondary_id>396936</secondary_id>
    <secondary_id>CEP001/11</secondary_id>
    <nct_id>NCT01297634</nct_id>
  </id_info>
  <brief_title>Radial Diffusion of the Botulinum Toxin Type A (Botox®): Electromyographic Evaluation of the Frontal Muscle</brief_title>
  <official_title>Phase IV Study of Radial Diffusion of the Botulinum Toxin Type A: Electromyographic Evaluation of the Frontal Muscle.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ivo Pitanguy Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ivo Pitanguy Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the diffusion area (cephalic, lateral, medial and caudal points) of the
      botulinum toxin type A in the frontal muscle for usual concentrations and dilutions of the
      drug. A basal line control and After the application control will be made, and the
      investigators will evaluate the drug effects, based on clinical aspects, photographic
      registers and through electromyography exam (EMG).

      Considering the results of our investigation, the investigators may propose a pattern of
      application of BOTULINUM TOXIN TYPE-A Botox® in the frontal area.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Area</measure>
    <time_frame>Change from baseline at day 30</time_frame>
    <description>Radial area (cephalic, lateral, medial and caudal points) of physioelectric activity of the frontal muscle, measured with electromyography (EMG).
Clinical and Photographical register evaluation of the dynamical wrinkles in the treatment area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Treatment Phase</measure>
    <time_frame>Day 30</time_frame>
    <description>Quantity of Botulinum Toxin used in every subject to aim to complete the treatment to the rest of the frontal area, based on the results of the primary outcomes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type-A 1U</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type-A 2U</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Type-A 3U</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type-A (day 0)</intervention_name>
    <description>Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.</description>
    <arm_group_label>Botulinum Toxin Type-A 1U</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type-A (day 0)</intervention_name>
    <description>Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.</description>
    <arm_group_label>Botulinum Toxin Type-A 2U</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type-A (day 0)</intervention_name>
    <description>Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.</description>
    <arm_group_label>Botulinum Toxin Type-A 3U</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have indication for aesthetic treatment of the frontal dynamic wrinkles,
             in maximal contraction of the frontal muscle.

          -  Availability and understanding of the patient, for complete all the steps throughout
             the duration of the study.

          -  Medical history and physical examination compatible with the study.

          -  Informed consent signed.

        Exclusion Criteria:

          -  Subjects with previous forehead face lifting or blepharoplasty surgery.

          -  Previous use of Botulinum toxin in the last 6 months.

          -  Forehead or eyelid asymmetry.

          -  Subjects with infections on site of injection or inflammatory skin diseases.

          -  Subjects with hypersensitivity to any component of the formulation, including albumin.

          -  Subjects with neuropathic or neuromuscular diseases.

          -  Subjects using aminoglycosides, penicillamine antibiotics, quinine and Ca2+ channel
             blockers.

          -  Subjects with pregnancy and lactation, or that planning become pregnant during the
             time of the study.

          -  Subjects with dimorphism or others psychological disorders.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ivo Pitanguy Institute</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>22280-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2011</study_first_posted>
  <last_update_submitted>November 22, 2011</last_update_submitted>
  <last_update_submitted_qc>November 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ivo Pitanguy Institute</investigator_affiliation>
    <investigator_full_name>Armando Iniguez MD</investigator_full_name>
    <investigator_title>Plastic Surgeon</investigator_title>
  </responsible_party>
  <keyword>Botulinum toxin type A</keyword>
  <keyword>Hyperfunctional forehead lines</keyword>
  <keyword>Randomized controlled trial</keyword>
  <keyword>Double-blinded trial</keyword>
  <keyword>Electromyogram (EMG)</keyword>
  <keyword>Electromyographic activity</keyword>
  <keyword>Frontal Area</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

